B3B

About B3B

This author has not yet filled in any details.
So far B3B has created 196 entries.

GE Healthcare Bets Big on Boston

Opens Life Sciences North American HQ to Accelerate Precision Medicine

Intro of GE press release:

“GE Healthcare’s Life Sciences business, a global provider of technologies and expertise to the biopharmaceutical and life sciences industries, today opened its new 210,000 square-foot North American headquarters in Marlborough, Massachusetts. At full capacity in 2017, it will employ more than 500 […]

June 24th, 2016|

Rapid Detection of Zika & Future Pandemics

From Wyss Institute: “The rapid emergence of the Zika virus on the world stage calls for a detection system that is just as quick. In this episode of Disruptive, Wyss Core Faculty member and MIT professor Jim Collins and University of Toronto Assistant Professor Keith Pardee discuss how they developed a low cost, paper-based […]

June 23rd, 2016|

Boston Business Journal: Zika Virus Test OK’d

(NOTE: You may have to disable ad-blocking to view video) From NECN: “A test developed in Massachusetts to detect the presence of the zika virus in blood has gotten FDA approval. Boston Business Journal’s Don Seiffert joins us with more”

June 22nd, 2016|

Life In The Trenches Of A Biotech LLC

Jeb Keiper, CBO of Nimbus Therapeutics LLC, has written a great blogpost (as part of the “From The Trenches” feature of LifeSciVC) about corporate financing, program-focused subsidiaries, the differences between “inc.” and “llc”, and much more. The intro:

“Unsurprisingly, I had not given that much thought to the parent entity of my new employer when […]

June 21st, 2016|

Bill Gates Talks Biotech

Coverage from Bill Gates speaking at the ASM Microbe 2016 conference at the Boston Convention & Exhibition Center:

Excerpt from his special Q&A with STAT:

“We heard that you met with some scientists here to have some one-on-ones. We’re curious about your personal interest in science.

It’s a very fun part of my job. Last week, I […]

June 17th, 2016|

How to Pay for Cutting-Edge Drugs?

In the feature “Promising gene therapies pose million-dollar conundrum,” Erika Check Hayden/Nature details how stakeholders in various segments of the life sciences and healthcare are trying to wrangle through the financial/pricing knots of gene therapies.

The intro:

“Drugs that act by modifying a patient’s genes are close to approval in the United States, and one is already available in Europe. […]

June 15th, 2016|

Vedanta Nabs $50M

Coverage on PureTech’s microbiome biotech, Vedanta Biosciences, raising $50M:

“Exploration of the human microbiome has spurred countless questions about the impact the trillions of microbes in and on our bodies have on our health. Those questions have led to a growing number of new biotech companies. One of the first to launch, Vedanta Biosciences of Cambridge, MA, […]

June 6th, 2016|

Taking Gene-Editing to the Next Level

Researchers from Broad Institute of MIT and Harvard program C2c2 to manipulate cellular RNA

Intro of the coverage from Scientific American:

“Researchers who discovered a molecular “scissors” for snipping genes have now developed a similar approach for targeting and cutting RNA. The new cutting tool should help researchers better understand RNA’s role in cells and diseases, […]

June 3rd, 2016|

Plan to Fabricate a Genome Raises Questions on Designer Humans

Antonio Regalado of MIT Technology Review writes about the recent proposal of some scientists to create a human genome “from scratch” – the intro of the feature:

“A proposal by a group of scientists and businesspeople to synthesize a human genome from scratch is attracting sharp criticism for dodging the big ethical questions such a step […]

June 2nd, 2016|

Why Sarepta’s Shares Slumped

From Dan Caplinger/Motley Fool:

“Sarepta Therapeutics plunged 27% after the Food and Drug Administration released information that could threaten the company’s ability to maximize profits if its treatment for Duchenne muscular dystrophy eventually receives FDA approval. The FDA’s recommendations centered on its compassionate use policy, saying companies generally could only get paid to offset its […]

June 2nd, 2016|
X